Latest news with #CMS
Yahoo
36 minutes ago
- Business
- Yahoo
Northland sees ‘key positive' for MiMedx in CMS rule proposal
Northland analyst Carl Byrnes says the CMS is taking action to curb skin substitute spending with its 2026 physician fee schedule proposed rule released last night. The rule would eliminate separate selling prices and 6% reimbursement in physician offices and replace it with a single capped payment rate, the analyst tells investors in a research note. Northland expects the hospital outpatient prospective payment system proposal to post imminently and follow a similar structure. It sees this as a 'key positive' for MiMedx (MDXG). The new framework supports reimbursement stability for the company and preserves access to clinically justified products, contends the firm. It keeps a Buy rating on MiMedx with a $12 price target The stock in premarket trading is down 11% to $6.05. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on MDXG: Disclaimer & DisclosureReport an Issue Organogenesis selloff on CMS proposal 'may be incorrect,' says BTIG Organogenesis, MiMedx fall after CMS rule to cut skin substitutes spending MiMedx management to meet with Northland MiMedx Group Holds Annual Shareholder Meeting MiMedx pullback presents 'compelling entry point,' says Northland Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
2 hours ago
- Business
- Yahoo
CVRx Announces Positive News on Outpatient Payment for Barostim
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ('CVRx'), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting. CMS is also soliciting comments about the need for a Level 6 Neurostimulator APC. We expect CMS will publish the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule in November, which is expected to take effect on January 1, 2026. This proposal follows two other positive developments in the last nine months relating to reimbursement rates. As of Oct. 1, 2024, Barostim was assigned to a higher paying MS-DRG for inpatient procedures. In that same month it was announced that Barostim will transition from Category III to Category I CPT codes for physician payments as of Jan. 1, 2026. These reimbursement updates underscore the clinical value of Barostim and reinforce its role in the heart failure care continuum. 'We appreciate CMS' proposal to keep Barostim in APC 1580, ensuring appropriate payment for the Barostim implant procedure,' said Kevin Hykes, President and CEO of CVRx. 'These reimbursement updates, along with the favorable proposed payment levels included in the recently released physician fee schedule, allow us to continue our progress toward expanding access to Barostim for patients suffering from heart failure with reduced ejection fraction, which we believe will help support its broader market adoption and long-term growth.' About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit Forward Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements about the proposal to maintain the APC for the Barostim implant procedure and progress toward expanded access to Barostim are forward-looking statements. These statements speak only as of the date of this press release and are based on our current expectations and projections about future events, and are subject to a number of known and unknown risks and uncertainties that could cause actual results to differ from our expectations, including the final OPPS rule, which could differ from the proposed rule, following the public comment period, and the actual impact of the APC on actual reimbursement and patient access. These forward-looking statements speak only as of the date of this press release. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Media Contact:Emily MeyersCVRx, Inc.763-416-2853emeyers@ Investor Contact:Mark Klausner or Mike VallieICR Healthcare443-213-0501ir@ in to access your portfolio
Yahoo
4 hours ago
- Business
- Yahoo
Weil, Gotshal & Manges and CMS lead European M&A legal advisers in H1 2025
Weil, Gotshal & Manges and CMS have emerged as the leading legal advisers in the European mergers and acquisitions (M&A) sector for the first half (H1) of 2025, according to the latest league table published by GlobalData. The report ranks legal firms based on the value and volume of M&A transactions they have facilitated. Weil, Gotshal & Manges secured the top position in terms of deal value, advising on transactions amounting to $20.6bn. In contrast, CMS led in deal volume, having provided counsel on 130 transactions during the same period. GlobalData lead analyst Aurojyoti Bose said: 'CMS was the clear winner by volume, outpacing its peers by a significant margin in H1 2025. It was the only adviser with triple-digit deal volume during the review period. Apart from leading by volume, CMS also held the eighth position by value in H1 2025. 'Meanwhile, Weil, Gotshal & Manges faced close competition from White & Case for the top position by value during H1 2025. It is noteworthy that White & Case was the top adviser by value in H1 2024 and missed the leadership position in H1 2025 by a whisker. While White & Case registered a decline in the total value of deals advised by it during H1 2025 compared to H1 2024, Weil, Gotshal & Manges registered more than a triple-fold increase. Resultantly, Weil, Gotshal & Manges' ranking by value jumped from 26th position in H1 2024 to the top position in H1 2025.' The analysis from GlobalData's Deals Database indicates that White & Case ranked second in value, advising on $20.4bn in deals. Kirkland & Ellis followed closely with $19.1bn, while A&O Shearman and Skadden, Arps, Slate, Meagher & Flom reported $17.9bn and $16.7bn, respectively. In terms of volume, White & Case also secured the second position with 65 deals, followed by A&O Shearman with 64 transactions. Cuatrecasas and Baker McKenzie completed the list with 50 and 37 deals, respectively. GlobalData's league tables are based on the real-time tracking of thousands of company websites, advisory firm websites and other reliable sources available on the secondary domain. A dedicated team of analysts monitors all these sources to gather in-depth details for each deal, including adviser names. To ensure further robustness to the data, the company also seeks submissions of deals from leading advisers. "Weil, Gotshal & Manges and CMS lead European M&A legal advisers in H1 2025" was originally created and published by Retail Banker International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Axios
4 hours ago
- Health
- Axios
Medicare proposes $8.1B boost for hospital outpatient care
The Trump administration wants to boost Medicare payments for hospital outpatient services by $8.1 billion next year — while simultaneously decreasing hospitals' reimbursement for services like chemotherapy. Why it matters: The payment proposal reveals that the administration is pushing hard for site-neutral reimbursements, or paying the same rate for services regardless of whether they're delivered in hospital outpatient facilities or doctors' offices. Hospitals typically bill Medicare more for the same services. Health systems have successfully lobbied against similar proposals in Congress in recent years. State of play: Hospital outpatient departments overall could expect a 2.4% increase in their Medicare payments, mostly due to an increase in the index that the Centers for Medicare and Medicaid Services uses to measure changes in prices. But Medicare administrators want to decrease what they pay hospitals to administer outpatient drugs at off-campus facilities, including chemotherapy, to make the sums equal to what is paid to physicians in private practices. This year, Medicare pays physician offices around $119 for a chemotherapy infusion, while off-site hospital outpatient facilities collected about $341, per the proposal. What it says: "We believe that financial incentives have driven volume from the office setting to the higher paying [outpatient department] setting, creating unnecessary increases in the volume of OPD services," the proposed rule states. CMS expects the change to decrease Medicare patients' cost-sharing by $70 million in 2026, and to reduce Medicare spending on hospital outpatient services by $210 million. The American Hospital Association called the proposal "inadequate." "We oppose the proposal to expand 'site-neutral' cuts and eliminate the inpatient-only list, as both policies fail to account for the real and crucial differences between hospital outpatient departments and other sites of care," Ashley Thompson, senior vice president of public policy analysis and development, said in a statement. CMS also wants to phase out over three years the list of services Medicare will only pay for when delivered in an inpatient setting. Medicare created the list in 2000 on the premise that some procedures could only be safely delivered at an inpatient hospital. The list currently includes 1,731 procedures. CMS proposed eliminating the list in 2021 but ultimately decided not to. Now, the agency says it's decided that innovations in medicine have made outpatient procedures much safer. "We agree with past commenters that the physician should use clinical knowledge and judgment, together with consideration of the beneficiary's specific needs, to determine whether a procedure can be performed appropriately in a hospital outpatient setting or whether inpatient care is required for the beneficiary," the proposal says.
Business Insider
11 hours ago
- Health
- Business Insider
CMS announces proposed rules for hospital payments in 2026
The Centers for Medicare and Medicaid Services issued the 2026 hospital outpatient prospective payment system and ambulatory surgical center payment system proposed rule. This proposal introduces 'a series of patient-focused reforms that would modernize payments, expand access to care, and enhance hospital accountability,' the agency said in a statement. CMS says the proposed changes are designed to: Reduce out-of-pocket costs for Medicare beneficiaries; Expand choices in where patients can receive care; Increase hospital accountability and transparency; and Safeguard the Medicare Trust Fund from waste and abuse. 'CMS seeks to equalize payments for certain services delivered in hospitals and off-campus facilities, helping ensure beneficiaries aren't penalized with additional copays simply based on where they receive care. The rule also proposes phasing out the inpatient-only list, which would give physicians greater flexibility to determine the most clinically appropriate setting for care and allow more patients to choose outpatient surgical options,' it added. Publicly traded companies in the hospitals space include Community Health (CYH), HCA Healthcare (HCA), Tenet Healthcare (THC) and Universal Health (UHS). Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with , delivered to your inbox every week.
